Skip to main content
main-content

14-06-2020 | Haematology | Video

EHA25 | Early data highlight potential of venetoclax–azacitidine in relapsed or refractory MDS

Amer Zeidan discusses phase 1b trial findings demonstrating promising efficacy and manageable tolerability of venetoclax plus azacitidine in patients with relapsed or refractory myelodysplastic syndrome (5:55).

Funding for independent interviews at EHA25 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Image Credits